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of the disease 19 . It has been demonstrated that, during the life of ALS/PDC patients, L-BMAA accumulates in their central nervous system (CNS) as free amino acid or integrated in proteins 20 . Furthermore, in either familial or sporadic ALS, protein aggregates have been observed in the brain, suggesting that cellular clearance mechanisms -including the autophagy-lysosome pathway-may be impaired 21 . However, how the dysfunction of the autophagy-lysosome pathway contributes to the pathogenesis of ALS remains unclear. Although defects in autophagy genes may not be considered the direct cause of ALS, most of the ALS-associated genes are involved in the degradative pathways of autophagy 22 . For instance, mutations in p62 account for approximately 1% of ALS cases 23 ; they have been reported also in about 2% of FTD (Frontotemporal Dementia) patients and in the most common form of ALS related to C9orf72 24, 25 . Therefore, dysfunctional autophagy may exacerbate disease phenotype 26 . This suggests that autophagy and its machinery may be an attractive therapeutic target for the prevention and treatment of ALS-associated neurodegeneration [27] [28] [29] [30] . In particular, boosting the efficiency of autophagy could ameliorate the toxic effects of aggregates in ALS 31 . In this respect, the mTORC1 inhibitor rapamycin and the autophagy-inducing agent trehalose are able to improve prognosis in TDP-43 mutant- 29 and in SOD1 mutantmice 32 , respectively. An important ionic regulator of autophagy is the first member of the mammalian mucolipin transient receptor potential (TRP) subfamily named TRPML1 or mucolipin-1, a cation-permeable channel predominantly localized on the membrane of lysosome. It is a non-selective cation channel 33 mainly involved in Ca 2+ signaling during lysosomal fusion with other membranes 34 . Interestingly, a deficiency of TRPML1/mucolipin-1 causes mucolipidosis IV, a lysosomal storage disease characterized by neurodegeneration [35] [36] [37] . Importantly, TRPML1 activation leads to lysosomal Ca 2+ release and calcineurin-dependent TFEB nuclear translocation 38 . In addition, it has been recently demonstrated that TRPML1 is also involved in lysosomal biogenesis 39 . Because of the importance of lysosomal function in ALS, we hypothesized that this channel could be compromised in the disease. We thus investigated whether the pharmacological activation of TRPML1 by its agonist ML-SA1 could exert a neuronal protection by modulating authophagy. Furthermore, since ALS is associated to 
Results

TRPML1 co-localizes with the endoplasmic reticulum (ER) in differentiated Mouse Motor Neuron-Like Hybrid Cells (NSC-34).
A tight coupling between ER proteins and lysosomes has been described in many cells 42 . Interestingly, we showed that the main lysosomal Ca 2+ channel TRPML1 was highly expressed in NSC-34 motor neurons and co-localized with the ER Ca 2+ sensor STIM1 (Fig. 1A ,a-e and Supplementary Fig. S1 ) as well as with the ER specific probe ER-dsRED ( Supplementary Fig. S1 ). Interestingly, TRPML1 significantly co-immunoprecipitated with STIM1 (Fig. 1B) . Furthermore, the high degree of overlap between LAMP1 and STIM1 immunosignals (Fig. 1C,a-e) further confirmed the significant co-localization between lysosomes and ER in NSC-34 motor neuronal cells. Moreover, the channel was efficiently silenced in NSC-34 motor neurons by siRNA strategy (Fig. 1D ). Under these conditions, TRPML1 immunosignal was significantly reduced in NSC-34 cells treated with siRNA against the channel (Fig. 1E ,a'-d') compared to the control cells (Fig. 1E,a-d) . Furthermore, TRPML1/STIM1 co-localization was significantly reduced in NSC-34 cells treated with siRNA against TRPML1 (Fig. 1E) .
From a functional point of view, a rapid intracellular Ca 2+ ([Ca   2+ ] i ) increase was detected when NSC-34 motor neurons were exposed to ML-SA1 (1-30 μM) ( Fig. 2A) , the specific membrane-permeable synthetic agonist of TRPML1 previously characterized by Xu's group 43 . To further confirm the specificity of the agonist, TRPML1 was silenced in NSC-34 motor neurons. In these cells, ML-SA1 was less effective in determining [Ca 2+ ] i increase compared to the control cells (Fig. 2B) . To corroborate the specificity of ML-SA1 on TRPML1 activity in motor neurons, lysosome-targeted Ca 2+ imaging was adopted. ML-SA1 (10 μM) elicited a rapid increase of the fluorescent signal (λ 470 nm) associated with lysosomal Ca 2+ efflux in NSC-34 cells transfected with GCaMP3-ML1 construct (Fig. 2C, left) , a single wavelength genetically-encoded Ca 2+ indicator engineered to the cytoplasmic N-terminus of TRPML1 43 . Interestingly, in a subset of cells, the SERCA blocker thapsigargin (1 μM) produced a www.nature.com/scientificreports www.nature.com/scientificreports/ large increase of Ca 2+ signal in NSC-34 transfected with GCaMP3-ML1 construct (Fig. 2C, right) . These data are in accordance with the hypothesis that ER may serve as primary source of Ca 2+ for lysosome 44 .
Lysosomal Ca 2+ dysregulation is associated with TRPML1 protein downregulation in primary motor neurons exposed to L-BMAA. Due to the functional coupling between ER and lysosomes under physiological conditions, we have investigated the relationship between these organelles in primary motor neurons chronically exposed to the neurotoxin L-BMAA. To this aim, we studied whether TRPML1-mediated lysosomal Ca 2+ release could be altered in the proposed neurotoxic model, by detecting the channel protein expression and activity. Figure 3A ,B showed that TRPML1 protein expression was progressively downregulated in primary motor neurons exposed to 24 and 48 h of L-BMAA compared to the untreated controls (Fig. 3A,B) . On the other hand, the lysosomal marker LAMP2 was not reduced (Fig. 3A,B) . Similar results were obtained in differentiated NSC-34 cells (Supplementary Fig. S2 ).
Then, we investigated whether TRPML1-mediated lysosomal Ca 2+ release was altered under these conditions. In accordance with the reduced protein expression of TRPML1, ML-SA1 (10 μM) elicited a lower lysosomal Ca 2+ efflux in primary motor neurons exposed to L-BMAA than in control neurons (Fig. 3C,D) . That lysosomal Ca 2+ content was reduced after L-BMAA exposure was confirmed by the reduction in lysosomal Ca 2+ discharge elicited by the membrane-permeable dipeptide GPN (300 μM) in motor neurons treated with the toxin (Fig. 3E ). Under the same experimental conditions (i.e. 48 h of L-BMAA), a significant ER Ca 2+ depletion occurred in primary motor neurons, as revealed by the low amount of ER Ca 2+ released after the addition of ATP + thapsigargin (Fig. 3F ). The same results were obtained in differentiated NSC-34 cells ( Supplementary Fig. S2 ).
TRPML1 dysfunction impairs the autophagic flux in primary motor neurons exposed to L-BMAA.
Macroautophagy is defective in TRPML1-deficient neurons 45 whereas TRPML1 overexpression results in a www.nature.com/scientificreports www.nature.com/scientificreports/ significant increase of the autophagic flux 46 . In order to verify the role of TRPML1 in the modulation of autophagy in primary motor neurons, we tested the effect of ML-SA1 alone on some autophagy initiators. The addition of ML-SA1 progressively induced the phosphorylation of AMP-activated protein kinase (p-AMPK), that is thought to activate autophagy through the inactivation of mTOR complex-1, and increased the expression of beclin 1 (Fig. 4A,B) , that is involved in the formation of the autophagosomes. Interestingly, under these conditions, ML-SA1 did not affect fluorescence labeling of axonal neurofilament H detected by NF200 in rat primary motor neurons (in arbitrary units: 20.156 ± 5.824 in control conditions vs 19.193 ± 1.546 in ML-SA1-treated neurons) ( Supplementary Fig. S3 ). On the other hand, to test the hypothesis that TRPML1 reduction could worsen while channel activation could ameliorate autophagy defects in ALS, lysosomal degradation pathway was investigated in this neurotoxic model. L-BMAA (300 μM/48 h) induced a significant increase in the expression of both p62/ SQSTM1 (Fig. 4C ) and LC3-II (Fig. 4D ) that were significantly reduced in the presence of ML-SA1 (Fig. 4C,D) . Since bafilomycin further increased LC3-II expression in L-BMAA-treated motor neurons, the exposure to the toxin impaired the autophagic flux in primary motor neurons (Fig. 4E,F) .
TRPML1 activation rescues motor neurons from L-BMAA-induced cell death.
To study the effect of ML-SA1 on L-BMAA-induced cell death, we tested the effect of this toxin in the absence of TRPML1 channel. TRPML1 protein expression was reduced by 70 ± 1.5% (*p < 0.05 vs control + siControl) in primary motor neurons treated with specific siRNA against the channel (Fig. 5A) . Functionally, ML-SA1 (10 μM) determined www.nature.com/scientificreports www.nature.com/scientificreports/ a significant Ca 2+ release in primary motor neurons that was significantly reduced in the absence of TRPML1 (Fig. 5B) .
Interestingly, the preincubation for 1 h with ML-SA1 (10 μM) reduced L-BMAA-induced cell death in primary motor neurons (Fig. 5C ) as well as in differentiated NSC-34 motor neurons, in which the neuroprotective effect occurred also for longer exposures (Supplementary Fig. S2 ). Importantly, the ML-SA1-induced neuroprotection was counteracted by TRPML1 silencing in primary motor neurons (Fig. 5C) . Furthermore, ML-SA1 pretreatment reduced GRP78 and caspase 9 upregulation induced by L-BMAA in primary motor neurons (Fig. 5D-F) .
As a consequence of cell suffering avoidance, the preincubation with ML-SA1 prevented TRPML1 protein downregulation induced by chronic exposure to L-BMAA (Supplementary Fig. S3 ).
Discussion
In recent years, the idea of lysosomes as mere degradative organelles has dramatically changed and they are now recognized as critical regulators of cellular homeostasis and survival. In the present study, we have characterized the involvement of one of the main lysosomal channels, TRPML1, in the pathogenesis of L-BMAA-induced ALS/PDC. We found that TRPML1 Ca 2+ channel is an important player in the protective response of lysosomes against L-BMAA in primary motor neurons chronically exposed to the neurotoxin. In fact, we provided evidence that TRPML1 was progressively downregulated in L-BMAA-treated neurons while its early stimulation, by the synthetic compound ML-SA1, efficiently rescued motor neurons from L-BMAA toxicity by counteracting ER stress and autophagy impairment (Fig. 6) . Furthermore, under these conditions, TRPML1 protein expression was partially restored as a consequence of ML-SA1-induced neuroprotection.
That ML-SA1 stimulated specifically TRPML1 channel was demonstrated by the absence of the effect on Ca 2+ release in TRPML1-silenced motor neurons. Furthermore, ML-SA1 failed to rescue motor neurons exposed to L-BMAA when TRPML1 was absent. Mechanicistically, lysosomal Ca 2+ efflux through TRPML1 seems to play a ] i increase. Each bar represents the mean ± S.E. (n = 20 cells studied in three different experimental sessions). *p < 0.05 vs basal values **p < 0.05 vs siControl. (C) Bar graph depicting the effect of ML-SA1 on cell viability rate of rat primary motor neurons exposed to L-BMAA (300 μM/48 h) in the presence or absence of siRNA against TRPML1. Data are expressed as mean ± S.E. of three different experimental sessions. *p < 0.05 vs control; **p < 0.05 vs L-BMAA alone; ***p < 0.05 vs ML-SA1 + L-BMAA. (D-F) Representative Western blotting and quantification of GRP78 (E) and caspase 9 (F) expression in rat primary motor neurons exposed to L-BMAA (300 μM/48 h) in the absence or presence of ML-SA1 (10 μM). Each bar represents the mean ± S.E. of data obtained from three different sessions. *p < 0.01 vs control; **p < 0.05 vs L-BMAA. For all, ML-SA1 was preincubated for 1 h before L-BMAA exposure.
www.nature.com/scientificreports www.nature.com/scientificreports/ prominent role in the protective action of ML-SA1. In fact, lysosomal Ca 2+ efflux progressively reduced together with TRPML1 protein expression in motor neurons exposed to the toxin, thus causing lysosomal Ca 2+ dysfunction and cell death. Furthermore, we showed a concomitant dysfunction in ER Ca 2+ homeostasis in neurons exposed to L-BMAA, most likely depending on the disruption of the lysosomal and ER functional interplay. Indeed, the present study suggests that ER store acts as a major source of lysosomal Ca 2+ in motor neurons and that dysfunctional Ca 2+ homeostasis in one of these organelles has a dramatic repercussion on the other store. This is in accordance with the evidence demonstrating the strategic role of ER in promoting lysosomal Ca 2+ refilling in other cellular systems 44 . Accordingly, we showed that the specific and irreversible SERCA inhibitor thapsigargin, by depleting ER Ca 2+ store, influences lysosomal Ca 2+ content measured as Ca 2+ release through TRPML1 by the Ca 2+ indicator GCaMP3-ML1. Furthermore, in the present study, ML-SA1 prevented the upregulation of the ER stress marker GRP78 that significantly increases after L-BMAA-induced ER store dysfunction 41 and in sporadic ALS characterized by misfolding of wild-type SOD1 40 . This suggests that TRPML1 stimulation may protect motor neurons from ER stress in different forms of ALS. It could be taken into consideration that, in general, an abundance of ER Ca 2+ is vital for nascent protein folding and cell survival 47 . Loss of ER luminal Ca 2+ is frequently accompanied by ER stress and by the activation of an apoptotic pathway. Therefore, ER Ca 2+ refilling is essential for cell survival under stress conditions 48 . Accordingly, it has been suggested that store-operated calcium entry upon ER calcium depletion is aberrant in SOD1 G93A animals 49 . However, our data showed that, in consideration of the close proximity between the two organelles, TRPML1-dependent lysosomal Ca 2+ release may also contribute to ER Ca 2+ filling state and to ER stress prevention by a continuous refilling of Ca 2+ ions. Therefore, we hypothesize that ER and lysosomes co-localization, together with their functional interdependency, can be crucial in the reduction of the neurotoxic effect of L-BMAA.
The toxicity caused by protein misfolding or aggregation, or proteotoxicity, is a common feature of ALS 50 . Ubiquitin-positive inclusions linked to SOD1, TDP-43, FUS, and C9orf72 have been reported in familial ALS 51 . However, abnormal accumulation of the wild-type form of some proteins, such as TDP-43 and SOD1, has also been observed in sporadic ALS 5, 40, 52 . This is indicative of defects in cellular cleansing mechanisms occurring in the neurodegenerative disease. Given the important role of autophagy in cleansing the cell of defective organelles and misfolded proteins, our data suggest that the activation of TRPML1 could prevent the engulfment in autophagy provoked by chronic exposure to L-BMAA. In fact, TRPML1 stimulation reduced the accumulation of p62/SQSTM1 and LC3-II in motor neurons exposed to the toxin. In this respect, p62 is known to be involved not only in selective autophagy but also in degradation through the ubiquitin-proteasome system 53 . Interestingly, overexpression of p62/SQSTM1 shortens lifespan in a double transgenic ALS mouse model by compromising the protein degradation pathway 54 . On the other hand, Curcio-Morelli and co-authors showed that mouse TRPML1-deficient neurons show a 2-fold increase in p62/SQSTM1 levels, defect in LC3-II clearance, macroautophagy impairment and increase in polyubiquitin levels 45 . This may suggest that TRPML1 is specifically involved in the impairment of the cleansing machinery in ALS.
Recent studies suggest that the aggregation of ALS-related genes can affect early steps in the autophagic process thus producing a hyperactive induction of autophagy suggestive of AMPK activation and mTOR repression in motor neurons of SOD1 G85R mice 55 . This determines autophagy engulfment. Consistently, upregulation of beclin 1 56 has been found in spinal cord and brainstem fractions of SOD1 G93A animals in which p62 and LC3-II levels were elevated 57 . The engulfment of autophagy was confirmed by the present study in motor neurons exposed to L-BMAA, since the neurotoxin increased the level of the autophagy markers p62 and LC3-II. However, we showed that TRPML1 stimulation by ML-SA1 prevented the elevation of these markers, thus rescuing the intact autophagic flux.
The therapeutic utility of pharmacological upregulation of autophagy in some neurodegenerative diseases 58 and in ALS models 59 is supported by a wealth of data. Nonetheless, enhanced autophagy seems to further exacerbate axonal degeneration and disease phenotype 50, 60 . This is indicative of an urgent need for other strategies aimed at finely regulating autophagy to promote neuronal protection and survival. To date, it has been reported that 
. The present study suggests that, at least in vitro, the initial triggering of lysosomal Ca 2+ release by TRPML1 stimulation could promote a sort of autophagy reprogramming leading to a long-lasting effect. Altogether, this study shows that the specific membrane-permeable synthetic agonist of TRPML1, ML-SA1, rescued motor neurons from death induced by chronic exposure to L-BMAA. Furthermore, ML-SA1 prevented the elevation of the ER stress marker GRP78 and of the autophagy-related proteins p62/SQSTM1 and LC3-II. Collectively, we propose that an early pharmacological stimulation of lysosomal Ca 2+ channel TRPML1 can efficiently rescue motor neurons from L-BMAA toxicity through the restoration of the autophagic flux.
Materials and Methods
Reagents. Rabbit polyclonal antibodies against TRPML1 (#ACC-081), STIM1-ATTO-550 (#ACC-063-AO) and STIM1 (#ACC-063) were purchased from Alomone Labs (Jerusalem, Israel); mouse monoclonal antibody against α-tubulin (#T5168), rabbit polyclonal anti-neurofilament 200 (NF200) (#N4142), and rabbit polyclonal antibody against LAMP2 (#L0668) were from Sigma-Aldrich (Milan, Italy); rabbit polyclonal antibody against LAMP1 (#AB2971) was from Merck Millipore (Darmstadt, Germany); rabbit polyclonal anti-p-AMPKα (#2531), anti-AM-PKα (#2532), and anti-GRP78 (#3183) antibodies were from Cell Signaling Technology, Inc. (Danvers, MA, USA); rabbit polyclonal antibodies against beclin 1 (#NB500-249) and p62 (#NBP1-48320) were from Novus Biologicals (Littleton, CO, USA); rabbit polyclonal antibodies against caspase 9 (#GTX132331) and LC3B (#GTX127375) were from GeneTex Inc. (Irvine, CA, USA). ECL reagents and nitrocellulose membranes were from GE Healthcare (Milan, Italy). siRNAs against TRPML1 and siRNA-control were purchased from Qiagen (Milan, Italy).
2-(2-Oxo-2-(2,2,4-trimethyl-3,4-dihydroquinolin-1(2H)-yl)ethyl)isoindoline-1,3-dione (ML-SA1) was from Merck Millipore (Darmstadt, Germany), while Gly-Phe β-naphthylamide (GPN) was from Santa Cruz Biotechnology, Inc. 
Cell cultures. Clonal cells. Mouse Motor Neuron-Like Hybrid Cells (NSC-34) were grown in high-glucose
Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 100 IU/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich, Milan, Italy). Cells were cultured at 37 °C in a humidified atmosphere with 5% CO 2 . Differentiation of NSC-34 cells was promoted by exposing cells to retinoic acid at 10 μM for 48 h, a condition triggering a typical neuronal phenotype 62 .
Primary cultures of rat motor neurons. Rat primary motor neurons were isolated from the spinal cord of 12-14-day old Wistar embryos and cultured as previously described 41, 63 . To prevent non-neuronal cell growth, cytosine β-D-arabinofuranoside hydrochloride (Ara-C; 10 μM) was added to the cell culture medium at 4 and 8 DIV. These primary cultures were used for experiments at 10-12 DIV.
L-BMAA and ML-SA1 administration. Motor neurons were exposed to 300 μM L-BMAA for 24 and 48 h. ML-SA1 (10 μM) was added to the cell culture medium 1 h before L-BMAA treatment. The chronic exposure to this non-proteic amino acid has been associated to ALS/PDC, a Guamanian form of ALS affecting Chamorro people 19 .
Immunocytochemistry and confocal microscopy. Twenty-four hours after transfection with ERdsRED and siTRPML1, NSC-34 cells were washed twice in cold 0.01 M PBS (pH 7.4) and fixed at room temperature in 4% paraformaldehyde for 20 min. Following three washes in PBS, cells were blocked in PBS containing 3% BSA for 30 min and then incubated overnight at 4 °C with anti-TRPML1 antibody (1:1000). In another set of experiments, NSC-34 cells were incubated with anti-TRPML1 (1:1000) or anti-LAMP1 (1:500) antibody and STIM1-ATTO-550 (1:200) (overnight at 4 °C). Then, cells were washed with PBS and incubated with anti-rabbit Cy2-conjugated antibody (1:200, Jackson Immuno Research Laboratories, Inc. PA, USA) for 1 h at room temperature under dark conditions. Cells were finally incubated for 5 min with Hoechst. Controls of the method in the double immunofluorescence experiments included the replacement of primary antibodies against TRPML1 or LAMP1 with normal serum. In addition, the anti-rabbit Cy2-conjugated antibody was highly preadsorbed to the IgGs of numerous species. For immunocytochemical analysis of the image shown in Supplementary Fig. S3 , rat primary motor neurons were incubated overnight at 4 °C with anti-neurofilament 200 (NF200) antibody (1:1000). Finally, cover glasses were mounted with a SlowFade TM Antifade Kit (Molecular Probes, Life Technologies, Milan, Italy) and acquired by a 63X oil immersion objective using a Zeiss inverted 700 confocal microscope 64 . Co-localization between TRPML1 or LAMP1 and STIM1-ATTO-550 was analyzed by using the 'co-localization highlighter' plug-in for ImageJ Software (NIH, Bethesda, MA, USA). Before the analysis of co-localization, threshold settings for each image were determined, and quantification was accomplished by counting the number of TRPML1 or LAMP1 and STIM1 co-localized points per microscope field. Results were expressed as a percentage of co-localization 64 . Fluorescence intensity of TRPML1 was quantified as pixel intensity value with the NIH www.nature.com/scientificreports www.nature.com/scientificreports/ image software. Digital images were acquired with 63X objective and the same laser power settings were applied to all the photographs for each experimental set Small interfering RNAs. In primary motor neurons TRPML1 knocking-down was achieved by three different FlexiTube small interfering RNAs (siRNAs) against the channel (Qiagen, Milan, Italy). Neurons were transfected in OptiMem medium by HiPerFect Transfection Reagent with the non-targeting control and the following siRNAs (all at 10 nM):
(#1) Rn_LOC288371_4 (sense strand: 5′-GCAGAACGAGUUUGUUGUATT-3′; antisense strand: 5′-UACAACAAACUCGUUCUGCAG-3′), (#2) Rn_LOC288371_3 (sense strand: 5′-UGAUCACAUUUGACAAUAATT-3′; antisense strand: 5′5′UUAUUGUCAAAUGUGAUCAGG-3′), (#3) Rn_LOC288371_2 (sense strand: 5′-ACGAGAUCCCUGACUGUUATT-3′; antisense strand: 5′-UAACAGUCAGGGAUCUCGUTG-3′). Only siRNA #2 efficiently reduced TRPML1 expression in primary motor neurons. In NSC-34 cells TRPML1 knocking-down was achieved by the following FlexiTube siRNAs (Qiagen, Milan, Italy) (all at 10 nM): (#1) Mm_Mcoln1_2 (sense strand: 5′-GAUCACAUUUGACAAUAAATT-3′; antisense strand: 5′-UUUAUUGUCAAAUGUGAUCAG-3′), (#2) Mm_Mcoln1_5 (sense strand: 5′-CAAGAACCUCACACUGAAATT-3′; antisense strand: 5′-UUUCAGUGUGAGGUUCUUGTA-3′). In NSC-34 cells, TRPML1 protein expression was successfully reduced only by using siRNA #2.
Western blotting and immunoprecipitation. Cells were lysed by using an ice-cold buffer containing 20 mM Tris-HCl (pH 7.5), 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1% NONIDET P-40, 1 mM Na 3 VO 4, and a protease inhibitor mixture (Roche Diagnostics). After centrifugation (13,000 rpm, 4 °C, 30 min), the supernatants were collected. Protein concentration of each sample was calculated by the Bradford assay 69 . Proteins were separated on 10% sodium dodecyl sulphate-polyacrylamide gels for TRPML1, LAMP1, LAMP2, p-AMPKα, AMPKα, beclin 1, p62, GRP78, and caspase 9 expression, and on 15% sodium dodecyl sulphate-polyacrylamide gels for LC3 expression, and then electrotransferred onto 0.2 μm nitrocellulose membranes (GE Healthcare, Milan, Italy). Then, membranes were incubated with the following antibodies: anti-TRPML1 (1:1000), anti-LAMP1 (1:1000), anti-LAMP2 (1:1000), anti-p-AMPKα (1:500), anti-AMPKα (1:1000), anti-beclin 1 (1:1000), anti-p62 (1:1000), anti-LC3 (1:1000), anti-GRP78 (1:1000), anti-caspase 9 (1:1000), and anti-α-tubulin (1:2000) .
For the immunoprecipitation, cells were homogenized in a lysis buffer containing: 50 mM HEPES, 100 mM NaCl, 1.5 mM MgCl 2 , 1 mM PMSF, 0.2% Nonidet P-40, 5 μg/ml aprotinin, 10 μg/ml leupeptin, and 2 μg/ml pepstatin. Lysates were then cleared by centrifugation and immunoprecipitated (500 μg) with anti-STIM1 (1:200), or anti-TRPML1 (1:200) antibodies. After separation by SDS-PAGE, immunoblot analysis was performed by using anti-TRPML1 (1:1000), or anti-STIM1 (1:1000) antibodies, respectively.
Cell death analysis. Cell survival/death was assessed as mitochondrial activity by the 3[4,5-dim ethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) assay. After treatments, neurons were incubated with MTT for 1 h at 37 °C. Then, samples were collected in dimethyl sulfoxide (DMSO) and measured by using a spectrophotometer at 540 nm. The data were expressed as a percentage of cell viability compared to control cultures.
Statistical analysis. Data are expressed as mean ± S.E.M. Statistical analysis was performed with unpaired t-test or one-way analysis of variance followed by Newman-Keuls test. Statistical significance was accepted at the 95% confidence level (p < 0.05).
